Literature DB >> 12591588

A tri-ethnic examination of symptom expression on the positive and negative syndrome scale in schizophrenia spectrum disorders.

Concepcion Barrio1, Ann Marie Yamada, Hazel Atuel, Richard L Hough, Simon Yee, Bryan Berthot, Patricia A Russo.   

Abstract

This study examined differences in symptom expression as measured by the Positive and Negative Syndrome Scale (PANSS [Schizophr. Bull. 13 (1987) 261]) in a tri-ethnic sample of persons diagnosed with schizophrenia. We hypothesized that ethnic differences would be more apparent in Positive Scale symptoms than in Negative and General Scale symptoms of the PANSS. The sample of 351 persons receiving services in community-based mental health clinics came from the initial phase of the San Diego site of the Schizophrenia Care and Assessment Program (SCAP), a longitudinal naturalistic study on the course of schizophrenia treatment. Participants were 88 African-Americans, 198 Euro-Americans, and 65 Latinos. Baseline PANSS scale scores and individual items were analyzed using Multivariate Analysis of Covariance procedures to examine symptoms by ethnic group and living situation while controlling for income, education, and age. There were no significant ethnic differences on the scale scores. At the item level of analysis, significant ethnic group differences were found in Hallucinatory Behavior, Suspiciousness, Excitement, and for Somatic Concerns. The cultural implications for the ethnic differences in each symptom behavior and the need for further research on symptom expression from an ethnographic perspective are discussed.

Entities:  

Mesh:

Year:  2003        PMID: 12591588     DOI: 10.1016/s0920-9964(02)00223-2

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  17 in total

1.  Effects of ethnicity on psychotropic medications adherence.

Authors:  Esperanza Diaz; Scott W Woods; Robert A Rosenheck
Journal:  Community Ment Health J       Date:  2005-10

2.  Eligibility, recruitment, and retention of African Americans with severe mental illness in community research.

Authors:  Michelle DeCoux Hampton; Mary C White; Linda Chafetz
Journal:  Community Ment Health J       Date:  2008-11-11

3.  Longitudinal treatment outcome of African American and Caucasian patients with first episode psychosis.

Authors:  Huijun Li; Shaun M Eack; Debra M Montrose; Jean M Miewald; Matcheri Keshavan
Journal:  Asian J Psychiatr       Date:  2011-10-12

4.  The new paradigm of recovery from schizophrenia: cultural conundrums of improvement without cure.

Authors:  Janis H Jenkins; Elizabeth Carpenter-Song
Journal:  Cult Med Psychiatry       Date:  2005-12

5.  The impact of immigration and visible minority status on psychosis symptom profile.

Authors:  Akiah Ottesen Berg; Ole A Andreassen; Sofie Ragnhild Aminoff; Kristin Lie Romm; Edvard Hauff; Ingrid Melle
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-06-14       Impact factor: 4.328

6.  Culturally Based Intervention Development: The Case of Latino Families Dealing With Schizophrenia.

Authors:  Concepción Barrio; Ann-Marie Yamada
Journal:  Res Soc Work Pract       Date:  2010-09-01

7.  Hope and burden among Latino families of adults with schizophrenia.

Authors:  Mercedes Hernandez; Concepción Barrio; Ann-Marie Yamada
Journal:  Fam Process       Date:  2013-07-17

Review 8.  Psychotropic medication nonadherence among United States Latinos: a comprehensive literature review.

Authors:  Nicole M Lanouette; David P Folsom; Andres Sciolla; Dilip V Jeste
Journal:  Psychiatr Serv       Date:  2009-02       Impact factor: 3.084

9.  Ethnic variation in symptoms and response to risperidone in youths with schizophrenia-spectrum disorders.

Authors:  Nick C Patel; M Lynn Crismon; Alan Shafer; Anthony De Leon; Molly Lopez; Daniel C Lane
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2006-02-08       Impact factor: 4.328

Review 10.  Ethnicity and variability of psychotic symptoms.

Authors:  William A Vega; Roberto Lewis-Fernández
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.